Biotechnology Assets Valuation Multiples

Biotechnology Assets Overview

About Biotechnology Assets

Biotechnology Assets SA is a clinical-stage biopharmaceutical company developing and producing biological products for the pharmaceutical and veterinarian sectors. It specializes in the prevention and treatment of niche diseases, such as orphan disease, antigens for new-generation vaccines, feed additives, and probiotics. Adl Bionatur offers a portfolio of non-therapeutic and therapeutic products to tier 1 and tier 2 animal health companies. The company's pipeline products include BNT006, BNT007, BNT010, and others.

Founded

2005

HQ

Employees

20

Website

biatgroup.com

Sectors

BiopharmaceuticalsBioTech

Financials (FY)

Revenue: $3M

EBITDA: ($790K)

EV

$26M

Valuation Multiples

Multiples.vc

Start free trial

Biotechnology Assets Financials

Biotechnology Assets reported last fiscal year revenue of $3M and negative EBITDA of ($790K).

In the same fiscal year, Biotechnology Assets generated $3M in gross profit, ($790K) in EBITDA losses, and had net loss of ($3M).

Biotechnology Assets P&L

In the most recent fiscal year, Biotechnology Assets reported revenue of $3M and EBITDA of ($790K).

Biotechnology Assets expects next 12-month revenue of XXX and NTM EBITDA of XXX

Biotechnology Assets Stock Performance

Biotechnology Assets has current market cap of $21M, and enterprise value of $26M.

Biotechnology Assets' stock price is $0.29.

Biotechnology Assets Valuation Multiples

Biotechnology Assets trades at 8.8x EV/Revenue multiple, and (32.9x) EV/EBITDA.

Biotechnology Assets Financial Valuation Multiples

As of April 18, 2026, Biotechnology Assets has market cap of $21M and EV of $26M.

Equity research analysts estimate Biotechnology Assets' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Biotechnology Assets has a P/E ratio of (6.2x).

Biotechnology Assets Margins & Growth Rates

Biotechnology Assets' revenue in the last fiscal year declined by (30%).

Biotechnology Assets' revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.3M for the same period.

Biotechnology Assets Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Biotechnology Assets M&A Activity

Biotechnology Assets acquired XXX companies to date.

Last acquisition by Biotechnology Assets was on XXXXXXXX, XXXXX. Biotechnology Assets acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Biotechnology Assets Investment Activity

Biotechnology Assets invested in XXX companies to date.

Biotechnology Assets made its latest investment on XXXXXXXX, XXXXX. Biotechnology Assets invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).